Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 494

1.

GM-CSF-secreting cancer immunotherapies: preclinical analysis of the mechanism of action.

Simmons AD, Li B, Gonzalez-Edick M, Lin C, Moskalenko M, Du T, Creson J, VanRoey MJ, Jooss K.

Cancer Immunol Immunother. 2007 Oct;56(10):1653-65. Epub 2007 Apr 5.

PMID:
17410360
2.

Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.

Li B, Simmons A, Du T, Lin C, Moskalenko M, Gonzalez-Edick M, VanRoey M, Jooss K.

Clin Immunol. 2009 Nov;133(2):184-97. doi: 10.1016/j.clim.2009.07.008. Epub 2009 Aug 7.

PMID:
19664962
3.

Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy.

Li B, Lalani AS, Harding TC, Luan B, Koprivnikar K, Huan Tu G, Prell R, VanRoey MJ, Simmons AD, Jooss K.

Clin Cancer Res. 2006 Nov 15;12(22):6808-16.

4.

Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb.

Li B, Lin J, Vanroey M, Jure-Kunkel M, Jooss K.

Clin Immunol. 2007 Oct;125(1):76-87. Epub 2007 Aug 13.

PMID:
17706463
5.

Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand.

Mach N, Gillessen S, Wilson SB, Sheehan C, Mihm M, Dranoff G.

Cancer Res. 2000 Jun 15;60(12):3239-46.

6.

Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors.

Li B, VanRoey M, Wang C, Chen TH, Korman A, Jooss K.

Clin Cancer Res. 2009 Mar 1;15(5):1623-34. doi: 10.1158/1078-0432.CCR-08-1825. Epub 2009 Feb 10.

8.
9.

Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.

Choi KJ, Kim JH, Lee YS, Kim J, Suh BS, Kim H, Cho S, Sohn JH, Kim GE, Yun CO.

Gene Ther. 2006 Jul;13(13):1010-20. Epub 2006 Mar 9.

PMID:
16525479
10.

Enhancement of the anti-tumor efficacy of a GM-CSF-secreting tumor cell immunotherapy in preclinical models by cytosine arabinoside.

Lin JM, Li B, Rimmer E, VanRoey M, Jooss K.

Exp Hematol. 2008 Mar;36(3):319-28. doi: 10.1016/j.exphem.2007.11.005.

PMID:
18279719
12.
13.

Novel membrane-bound GM-CSF vaccines for the treatment of cancer: generation and evaluation of mbGM-CSF mouse B16F10 melanoma cell vaccine.

Yei S, Bartholomew RM, Pezzoli P, Gutierrez A, Gouveia E, Bassett D, Soo Hoo W, Carlo DJ.

Gene Ther. 2002 Oct;9(19):1302-11.

14.
15.
16.

Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies.

Nelson WG, Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Kim M, Weber CE, Baccala AA, Goeman MA, Clift SM, Ando DG, Levitsky HI, Cohen LK, Sanda MG, Mulligan RC, Partin AW, Carter HB, Piantadosi S, Marshall FF.

Cancer Chemother Pharmacol. 2000;46 Suppl:S67-72.

PMID:
10950151
17.

Lymphocyte activation gene-3 fusion protein increases the potency of a granulocyte macrophage colony-stimulating factor-secreting tumor cell immunotherapy.

Li B, VanRoey M, Triebel F, Jooss K.

Clin Cancer Res. 2008 Jun 1;14(11):3545-54. doi: 10.1158/1078-0432.CCR-07-5200.

18.

Inhibition of murine melanoma growth by granulocyte-macrophage colony stimulating factor gene transfection is not haplotype specific.

Botella R, Sarradet MD, Potter LE, Lawley M, Galloway TH, Ansel JC, Armstrong CA.

Melanoma Res. 1998 Jun;8(3):245-54.

PMID:
9664146
19.

Effective immunization against neuroblastoma using double-transduced tumor cells secreting GM-CSF and interferon-gamma.

Bausero MA, Panoskaltsis-Mortari A, Blazar BR, Katsanis E.

J Immunother Emphasis Tumor Immunol. 1996 Mar;19(2):113-24.

PMID:
8732694

Supplemental Content

Support Center